|
FEBRUARY'S BEST FEATURED EDITORIAL |
|
|
Advancements In Targeted LNP Therapy | By Advancing RNA | We’re still striving to deliver mRNA-LNPs to cells/tissue types that go beyond the liver. Outside of exploring different lipid combinations to expand mRNA-LNPs’ deliverability to new tissues, this discussion featuring Dominik Witzigmann, John Zuris, and Sujit Jain investigated the industry’s push toward active delivery to improve targeting, as well as other advancements being made to improve LNP development, quality, & deliverability. |
|
|
Money In The Bank: Why 2025's Setbacks Were The Foundation RNA Needed | By Anna Rose Welch, editorial & community director, Advancing RNA | I saw 2025 as a year that was foundational for our efforts to learn more about the biology and function of our products. However, there were two developments in particular that, to me, encapsulated the trials, tribulations, and ultimately the success of an industry that is doing its damnedest to answer one of the biggest questions facing us: “Why RNA?” |
|
|
A New Space Race: Reclaiming Efficiency In The mRNA Industry | By Anna Rose Welch, editorial & community director, Advancing RNA | It goes without saying that efficiency in drug development is tantamount — especially when it comes to getting much-needed clinical data. So, when I asked Allan Shaw about the ongoing trends he anticipates seeing more of in 2026, he immediately pointed to the increasing prominence of overseas development, particularly in nations like Australia and China. |
|
|
FEBRUARY'S BEST INDUSTRY INSIGHTS |
|
|
|
|
|
FEBRUARY'S BEST SOLUTIONS |
|
|
|
|
|
.png){kind=logo}